Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2023 | Insights into mass spectrometry-based proteomics in multiple myeloma research

Arun Wiita • 29 Sep 2023
IMS 2023
Multiple Myeloma

Arun Wiita, PhD, University of California, San Francisco, CA, shares some insights into the use of mass spectrometry-based proteomics in multiple myeloma, highlighting the value of this novel approach in improving research in the field. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding: Roche/Genentech

More from Arun Wiita

Novel targets in multiple myeloma & the role of the immune system in disease progression 9:26
Novel targets in multiple myeloma & the role of the immune system in disease progression
Arun Wiita et al. • 12 Apr 2025
The value of genomics in multiple myeloma & applying this in clinical practice
Arun Wiita et al. • 3 May 2024
Addressing proteasome inhibitor resistance in multiple myeloma in the immunotherapy era 1:37
Addressing proteasome inhibitor resistance in multiple myeloma in the immunotherapy era
Arun Wiita • 29 Sep 2023
The importance of proteomics in myeloma and how this may be implemented in clinical practice 1:15
The importance of proteomics in myeloma and how this may be implemented in clinical practice
Arun Wiita • 29 Sep 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals